Pharmaceuticals Industry Trends Italy - 2022

Market Monitor

  • Italy
  • Chemicals/Pharma

15th March 2022

High days sales outstanding in the wholesalers segment

IT Italy pharma credit risk 2022

Italy´s pharmaceuticals industry accounts for about 2% of global production, with 85% of production exported. In general, Italian drug producers record high margins, but since H2 of 2021 they are being affected by a sharp increase in energy prices. Margins of wholesalers and distributors are generally tight, due to high transport costs, discounts to customers and outstanding receivables. On top, there is a 3% margin cap for sales of prescription drugs in the Italian market. Pharmacies try to compensate this with sales of supplements and cosmetic products.

IT Italy pharma output 2022

In Italy, public healthcare expenditure per capita amounts to EUR 280, 30% less than the EU average. While healthcare spending growth will be rather modest in 2022 and 2023, mid-and long-term demand will be driven by demographic developments. The ageing population in Italy will trigger an increase in medical treatments, in particular for chronic diseases.

In general, pharmaceutical producers are well capitalised and not highly geared. In contrast, capitalisation of wholesalers is often low and coupled with high indebtedness, high working capital requirements and steady investments in warehouses across the country, and related logistics. In this segment days sales outstanding (DSO) and days of inventory outstanding (DIO) are rather high and businesses require bank loans in order to compensate slow payments from their customers. It helps that banks are generally willing to provide loans to all subsectors, including this segment. The main reason is that pharmaceuticals is performing better than other Italian industries, with a history of low default rates. We expect that both non-payment notifications and insolvencies will remain low in 2022.

Our underwriting stance is very open for drug producers, due to low gearing, high margins and strong export performance. We have a prudent approach for wholesalers/distributors, in particular for businesses in cooperatives, as their solvency is dependent on the timely payment of their affiliates (pharmacies). The same accounts for pharmacies, due to strong competition from hospitals and para-pharmacies, which puts pressure on their margins.

Related documents

Disclaimer

Each publication available on or from our websites, such as, but not limited to webpages, reports, articles, publications, tips and helpful content, trading briefs, infographics, videos (each a “Publication”) is provided for information purposes only and is not intended as a recommendation or advice as to particular transactions, investments or strategies in any way to any reader. Readers must make their own independent decisions, commercial or otherwise, regarding the information provided. While we have made every attempt to ensure that the information contained in any Publication has been obtained from reliable sources, Atradius is not responsible for any errors or omissions, or for the results obtained from the use of this information. All information in any Publication is provided ’as is’, with no guarantee of completeness, accuracy, timeliness or of the results obtained from its use, and without warranty of any kind, express or implied. In no event will Atradius, its related partnerships or corporations, or the partners, agents or employees thereof, be liable to you or anyone else for any decision made or action taken in reliance on the information in any Publication, or for any loss of opportunity, loss of profit, loss of production, loss of business or indirect losses, special or similar damages of any kind, even if advised of the possibility of such losses or damages.